The transforming growth factor (TGF)-β has been identified as a master regulator of liver fibrogenesis. Thus, targeting TGF-β1 pathway might modulate chronic liver disease (CLD) development and/or progression in murine model. Galunisertib (Ly2157299), already in clinical studies phase II, is an oral small molecule targeting TGF-β type I receptor (ALK-5).
Creators: Seddik Hammad, Julia Werle
Contributor: Seddik Hammad
Computational models complement experimental methods in the analysis of tissue organization processes, and play an increasingly important role in systems biology and systems medicine. Creating and parameterizing mathematical models for the simulation of biological tissue dynamics at multiple scales is still a complex and resource-consuming task, which necessitates skills in diverse scientific disciplines. The software TiSim was conceived to facilitate programming, integration and deployment of
Contributor: Tim Johann